Therakos is a global pioneer in autologous immunomodulatory therapy delivered at the bedside through Extracorporeal Photopheresis (ECP). Supported by more than four decades of clinical experience and evidence-based medicine, the Therakos ECP system was among the first FDA-approved cell-based immunomodulatory therapies.

Our mission is to restore and protect human immunity. Rather than broadly suppressing the immune system, our approach is designed to help re-establish immune balance by harnessing the power of a patient’s own cells.

Through ongoing investment in research, evidence generation, and innovation, we are advancing the science of immunomodulation to expand understanding and improve outcomes for patients living with complex immune-mediated diseases.